Option Care Health (OPCH) Q3 2024 earnings summary

Executive summary

• Net revenue for Q3 2024 was $1.28 billion, up 17% year-over-year, driven by organic growth in both acute and chronic therapies, with strong performance in rare, orphan, and established therapeutic categories.

• Net income for Q3 2024 was $53.9 million, down 4.3% compared to Q3 2023, with a net margin of 4.2%.

• Gross profit margin declined to 20.1% from 23.3% year-over-year, mainly due to higher cost therapies, less favorable procurement dynamics, and supply chain disruptions.

• Operational recovery from the Change Healthcare incident is largely complete, with no material financial impact in Q3 2024, though patient payment collections remain delayed.

• Acute therapies faced significant supply chain disruption due to Hurricane Helene, impacting IV bag availability and limiting new patient onboarding, with effects expected to persist into Q4.

Financial highlights

• Q3 2024 operating income was $85.1 million, up 5% year-over-year; operating margin was 6.7%.

• Adjusted EBITDA reached $115.6 million, up 5.3% year-over-year, representing 9% of revenue.

• Cash flow from operations in Q3 was $160.4 million, up from $61.0 million a year ago; cash balance at quarter-end was $483.0 million.

• Share repurchases totaled $41.9 million in Q3 and $160.0 million for the nine months ended September 30, 2024.

• For the nine months ended September 30, 2024, net income was $151.7 million on $3.65 billion revenue.

Outlook and guidance

• Full-year 2024 net revenue expected between $4.9 billion and $4.95 billion; adjusted EBITDA guidance at $438–$443 million.

• At least $300 million in cash flow from operations anticipated for 2024; effective tax rate projected at 26%-28%.

• No 2024 impact from Stelara pricing changes; material gross profit impact expected in 2025 due to CMS negotiations and biosimilar competition, with further guidance to be provided in Q4 call.

• Guidance reflects anticipated negative impact from ongoing supply chain disruption.

• Medium-term outlook remains high single-digit top-line growth and low double-digit enterprise growth.